Drug intelligence / Profile preview

amphetamine

Development stage
Approved
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Inhalation, Intranasal
01

Overview

Amphetamine is a central nervous system (CNS) stimulant of the phenethylamine class, used primarily in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and occasionally obesity. It exists as two enantiomers—levoamphetamine and dextroamphetamine—with the racemic mixture being referred to as "amphetamine" proper. Amphetamine increases synaptic concentrations of monoamines, especially dopamine and norepinephrine, by promoting their release from presynaptic neurons and inhibiting reuptake. This results in increased alertness, concentration, energy levels, decreased appetite, and elevated mood. Discovered in 1887 by Lazăr Edeleanu and first marketed as Benzedrine in the 1930s for nasal congestion and later other indications including depression and weight loss. Today its use is highly regulated due to its potential for abuse[1][3][5].

Brand names
Adzenys ERAdzenys XR-ODTDyanavel XREvekeoEvekeo ODTAmphetamine Sulfate
Other names
amfetaminedesoxynorephedrinenorephedrane1-phenyI‑2‑aminopropanebeta‑aminopropylbenzenepropisaminepsychedrineraphetaminerhinalatorsimpatedrinsympatedrineactedron
02

Targets

VMAT2 (Vesicular monoamine transporter 2)TAAR1 (Trace amine-associated receptor 1)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on amphetamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amphetamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call